Due to the restricted BCMA expression pattern, BCMA was defined as the most suitable antigen to treat MM, and the design of novel and effective CAR-T-BCMA with CD28 [38] opened the path for a clinical trial in MM patients in 2016. The gene discussed is CD28; the disease is Miyoshi myopathy.